@entity3403 and other @entity2930 in the treatment of bone XXXX .

@entity1 @entity1214 @entity263 @entity0 @entity2930 @entity5 @entity19 @entity3403 @entity3 @entity803
The @entity803 family includes @entity803 , @entity3403 and @entity1214 , all of which have been used as antibiotics effectively for decades. New uses emerged for these compounds after their effect on mitochondrial function was discovered. Cytostatic and cytotoxic activity of these compounds was shown against cell lines of @entity5 origins. In addition, @entity2930 and chemically modified @entity2930 inhibit the activity of several matrix metalloproteinases (MMPs). Given the importance of these enzymes in @entity5 cell invasion and metastatic ability, the potential use of @entity2930 in @entity5 therapy needed to be investigated. Col-3, a chemically modified @entity803 , is now the subject of clinical trials in @entity5 @entity1 . However, the potential of @entity2930 in @entity5 therapy takes on an added dimension in the bone. MMPs have been shown to be important mediators of @entity3 formation in the bone, contributing largely to the morbidity of @entity0 and @entity263 @entity1 . The natural osteotropism of @entity2930 would allow them to be highly effective in the inhibition of MMPs produced by osteoclasts or @entity5 cells in the bone. This hypothesis has now been confirmed by experimental evidence showing that @entity3403 reduces @entity5 burden in a @entity19 model of @entity0 -derived osteolytic bone @entity3 . This effect is likely due to a combination of multiple roles of @entity3403 , including MMP inhibition and a negative effect on osteoclast differentiation and survival. These encouraging results have now paved the way for an ongoing trial of @entity3403 in early combination therapy for @entity0 and @entity263 @entity1 .
